Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979
Published October 11, 2023 · Recall initiated: October 3, 2023
Summary
FDA records drug Class III recall D-0040-2024, published October 11, 2023 and initiated October 3, 2023. Recalling firm: Imprimis NJOF, LLC; Status: Terminated; Reported quantity: 364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag); Lot: 23APR018. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Subpotent: Failing Test Results for Epinephrine
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Imprimis NJOF, LLC
- Distributor
- Nationwide
- Lot
- 23APR018
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection,January 14, 2026
- FDADexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC,January 14, 2026
- FDATri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, ImprimisJanuary 14, 2026
- FDAKlarity-C Drops (Cyclosporine) 0.1%, Preservative-Free Sterile Ophthalmic Emulsion, This is a compounded drug,November 26, 2025
- FDAHydrALAZINE Hydrochloride Tablets, USP, 10 mg, 100 Tablets (10 x 10) per carton, Rx Only, Distributed by:October 11, 2023
- FDATriamcinolone Acetonide Injectable Suspension, USP, 400 mg per 10 mL (40mg/mL), 10 mL Multiple Dose Vial, RxOctober 11, 2023
Questions about this recall
Was Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979 recalled?
Yes. FDA published recall D-0040-2024 on October 11, 2023. Reported hazard: Subpotent: Failing Test Results for Epinephrine
What should I do if I have this product?
Voluntary: Firm initiated · Letter